Ali Tehrani Biography and Net Worth

CEO of Zymeworks

Dr. Tehrani is one of our co-founders and has served as our President and Chief Executive Officer and as a member of our Board of Directors since the Company’s inception in September 2003. He has been an integral part of many of our corporate achievements including raising seed and angel financing and overseeing our technical operations and patent filings. Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani is a member of the board of directors at Creatus Biosciences Inc. and BIOTECanada and has served as a board director for the Student Biotechnology Network, CQDM, LifeSciences British Columbia, and on the MITACS Industrial Advisory Board. He was also a member of British Columbia’s Premier’s Technology Council from 2016 to 2018.

What is Ali Tehrani's net worth?: The estimated net worth of Ali Tehrani is at least $6.24 million as of July 15th, 2021. Dr. Tehrani owns 264,125 shares of Zymeworks stock worth more than $6,241,274 as of February 24th. This net worth approximation does not reflect any other assets that Dr. Tehrani may own. Learn More about Ali Tehrani's net worth.
How do I contact Ali Tehrani?: The corporate mailing address for Dr. Tehrani and other Zymeworks executives is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Ali Tehrani's contact information.
Has Ali Tehrani been buying or selling shares of Zymeworks?: Ali Tehrani has not been actively trading shares of Zymeworks during the past quarter. Most recently, Ali Tehrani sold 3,800 shares of the business's stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $36.00, for a transaction totalling $136,800.00. Following the completion of the sale, the chief executive officer now directly owns 264,125 shares of the company's stock, valued at $9,508,500. Learn More on Ali Tehrani's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last year, Zymeworks insiders bought shares 13 times. They purchased a total of 1,405,768 shares worth more than $16,773,032.28. During the last year, insiders at the sold shares 8 times. They sold a total of 187,933 shares worth more than $4,673,716.04. The most recent insider tranaction occured on January, 12th when CEO Kenneth Galbraith sold 30,424 shares worth more than $689,712.08. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/12/2026.

Ali Tehrani Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2021	Sell	3,800	$36.00	$136,800.00	264,125
7/12/2021	Sell	12,669	$36.12	$457,604.28	272,994
3/10/2021	Sell	4,392	$34.95	$153,500.40	264,717
12/7/2020	Sell	850	$56.16	$47,736.00	257,009
11/2/2020	Sell	3,500	$39.04	$136,640.00	257,009
4/3/2020	Buy	575	$33.39	$19,199.25	256,009
3/29/2019	Sell	3,000	$16.24	$48,720.00

Ali Tehrani Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $23.63

$22.80

$23.68

50 Day Range

MA: $24.19

$22.02

$27.62

2 Week Range

Now: $23.63

$9.03

$28.49

Volume

445,321 shs

Average Volume

777,076 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25